Objectives Cardiopulmonary involvement (CPI) is a major cause of morbidity and mortality in systemic sclerosis (SSc). The 6 min walk test (6MWT) is widely used to assess functional capacity, but its ...

Rheumatoid arthritis (RA) is an autoimmune disease that often evolves over several years, which in the presence of risk factors, is termed the at-risk phase. Several of the currently approved ...

Objective To investigate the presence and bioactivity of lipopolysaccharides (LPS) in synovial fluid (SF) of osteoarthritis (OA) patients and elucidate mechanisms modulating their inflammatory ...

Objectives Clinical features of Behçet’s disease (BD) exhibit significant variability, not only from patient to patient but also according to gender and geographical region. This study aims to ...

Background In routine care, Danish patients with psoriatic arthritis are monitored in the DANBIO registry. In March 2022, patient-reported outcome measures (PROMs) on selected non-musculoskeletal ...

Objective To investigate and distinguish detailed nailfold videocapillaroscopy (NVC) findings in patients with limited (lcSSc) and diffuse (dcSSc) cutaneous systemic sclerosis (SSc).Methods A total of ...

Objectives To investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis ...

Background Previous genome-wide association studies (GWAS) have identified numerous genetic loci associated with juvenile idiopathic arthritis (JIA). However, the functional impact of these ...

Original research: Molecular insights into the relationship between sustained CRP elevation and endothelial dysfunction in axial spondyloarthritis (5 July, 2025 ...

Background Patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) are at an increased risk for infection related to the use of immunomodulatory therapies (ITs). The objective of this ...

Jih- Jin Tsai, Li-Teh Liu, Chun-Hong Chen, et al. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open 2023;9:e003038.